World-first gonorrhoea vaccine programme set to be rolled out
The move, hailed as a 'landmark moment for sexual health', will aim to tackle rising levels of the sexually transmitted infection (STI).
It comes after the number of gonorrhoea cases in England topped 85,000 in 2023, the highest since records began in 1918, with warnings over some strains being resistant to antibiotics.
Gay and bisexual men with a recent history of multiple sexual partners or a bacterial STI will be eligible under the new programme, NHS officials said.
According to the Joint Committee on Vaccination and Immunisation (JCVI), gonorrhoea disproportionately impacts specific communities, such as deprived areas, people of black Caribbean ethnicity, and gay, bisexual and other men who have sex with men.
Diagnoses are highest among gay, bisexual and other men who have sex with men, the JCVI said.
UK Health Security Agency (UKHSA) data shows there was a 9.4% increase in gonorrhoea diagnoses among gay, bisexual and other men who have sex with men in 2023, with cases rising from 37,095 to 40,586.
The vaccine is an existing jab, known as 4CMenB, that is currently used to protect people against the meningococcal B disease, a serious bacterial infection that can cause meningitis and sepsis.
It is used in the routine childhood programme and given to babies at eight weeks, 16 weeks and one year.
Dr Amanda Doyle, national director for primary care and community services at NHS England, said: 'The launch of a world-first routine vaccination for gonorrhoea is a huge step forward for sexual health and will be crucial in protecting individuals, helping to prevent the spread of infection and reduce the rising rates of antibiotic resistance strains of the bacteria.'
Eligible patients will be identified and contacted in the coming weeks, with the jab offered through local authority-commissioned sexual health services from August 1.
And while at the appointment, patients will also be offered jabs for mpox, human papillomavirus (HPV), and hepatitis A and B.
Dr Doyle added: 'NHS teams across the country are now working hard to plan the rollout and ensure we hit the ground running, while the routine mpox vaccination programme builds on the vital progress the NHS has made in recent months in reaching as many eligible people as possible.'
Gonorrhoea is the second most common bacterial STI in the UK.
Symptoms can include green or yellow discharge from the vagina or penis, pain when urinating and pain and discomfort in the rectum.
For women, symptoms can include lower abdominal pain or bleeding between periods.
However, many people do not have symptoms.
The jab contains proteins from neisseria meningitidis – the bacteria that causes meningococcal disease – which is closely genetically related with neisseria gonorrhoeae, the bacteria that causes gonorrhoea.
The JCVI said studies suggest the 4CMenB vaccine has between 32.7 to 42% effectiveness against gonorrhoea, and while vaccination would slash the risk of becoming infected it would not eliminate it completely.
However, it stressed that vaccination would be beneficial, as previous gonorrhoea infection is thought to offer little protection against future infections.
The programme comes amid warnings that cases of gonorrhoea that are resistant to the antibiotic ceftriaxone – usually the first line of treatment – are on the rise in England.
This means the bacteria that causes the STI has developed the ability to survive and multiply even when exposed to the antibiotic.
Some cases are also classed as 'extensively drug resistant' – or XDR – meaning the infection did not respond to ceftriaxone or the second line of treatment.
In March, UKHSA revealed there were 17 cases of ceftriaxone-resistant gonorrhoea between January 2024 and March 2025.
In the same period, there were nine XDR cases reported, compared to five cases between 2022 and 2023.
Dr Sema Mandal, consultant epidemiologist and deputy director at UKHSA, said: 'This vaccination programme is a hugely welcome intervention at a time when we're seeing very concerning levels of gonorrhoea, including antibiotic resistant gonorrhoea.
'In 2023 we saw gonorrhoea diagnoses reach their highest since records began in 1918.
'Not only will this roll-out provide much needed protection to those that need it most, but it will make the UK the first country in the world to offer this protection and a world leader in protecting people against gonorrhoea.'
Health minister Ashley Dalton urged people to take up the vaccine offer 'not only keep each other safe but help tackle the growing threat of antibiotic resistance'.
She added: 'By targeting those most at risk, we can reduce transmission rates from this unpleasant disease that is becoming harder to treat and prevent thousands of cases over the next few years.'
Richard Angell, chief executive of Terrence Higgins Trust, described the jab as a 'game changer'.
'This alone could cut 40% of new gonorrhoea cases,' he said.
It comes after 12 new mpox vaccination sites opened across England in February, meaning every area in the country can now offer jabs to those at a higher risk of getting the virus.
Previously, vaccines were only available to eligible people at 19 sites across London, Brighton in East Sussex, and Manchester.
Professor Matt Phillips, president of the British Association for Sexual Health and HIV (BASHH), said: 'This is excellent news and a landmark moment for sexual health in England.
'A new gonorrhoea vaccination programme – alongside continued rollout of mpox vaccination – forms a vital part of our efforts to address the significant inequalities we are seeing in sexual health outcomes.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BreakingNews.ie
an hour ago
- BreakingNews.ie
Chris Hoy calls for systemic change in testing for prostate cancer
Six-time Olympic champion Sir Chris Hoy has called for systemic change in the ways men get tested for prostate cancer. The 49-year old cyclist was diagnosed with stage four prostate cancer in 2023 and was told last year that it has spread to his bones and is terminal. Advertisement NHS guidance says men over the age of 50 are at highest risk of developing prostate cancer, but Sir Chris wants to help men get screened earlier. He said: 'I was diagnosed with stage four prostate cancer at 47. By this age, my prostate cancer was advanced and could have been progressing from when I was 45 or even younger. 'With prostate cancer, the earlier you find it, the easier it is to treat. We need the system to change to enable more men to get diagnosed earlier, and stop them getting the news I got.' One option is a PSA blood test which checks the level of prostate-specific antigens in the blood, A high reading may be a sign of a prostate condition. Advertisement NHS guidance says these tests are not routinely used as they are not reliable, but men over 50 can ask GPs for one. Sir Chris's comments came after Prostate Cancer UK urged the UK government for an overhaul of NHS guidelines to encourage GPs to proactively speak to men at high risk from 45 years old. According to the charity, around one in eight men in the UK will get prostate cancer, which occurs when cells in the prostate start to grow in an uncontrolled way and, if not detected early, risks spreading. Sir Chris added: 'I believe men at highest risk, for example men with a family history like me or black men, should be contacted by their GP earlier on to discuss a simple PSA blood test that can check for signs of prostate cancer. Then if there are any issues, they can get it treated it at an earlier stage. Advertisement 'I've told my story to help raise awareness about the most common cancer in men and get more thinking about their risk and what they can do, but it shouldn't all be men's responsibility. 'I've faced many challenges in my life, and going public with my prostate cancer diagnosis was certainly one of them. 'I've been incredibly lucky to have so much support from my family, friends and the general public. The kindness has lifted me up and given me a sense of purpose, and I'm committed to taking that forward and using my platform to raise awareness of the most common cancer in men and help more men at risk to come forward and get tested.' The Scottish cyclist has launched his own charity cycling challenge, Tour de 4, with the aim of changing perceptions around stage four cancer. Advertisement The challenge will take place on September 7 in Glasgow with a final registration phase open for riders to sign up. Speaking about Sir Chris, Laura Kerby, chief executive at Prostate Cancer UK, said: 'His bravery and tireless work to raise awareness has already made a huge impact. 'In just a few months after Sir Chris went public with his diagnosis last year, over 286,000 people used our online risk checker to learn more about the disease, find out their own risk and learn what they can choose to do about it. 'His bravery has inspired so many men to take action, and he has undoubtedly saved lives. Advertisement 'One in eight men will get prostate cancer. The earlier it's found, the easier it is to treat — but there's currently no screening programme in the UK. So if, like Sir Chris, you have a family history of the disease, or if you're black, we strongly encourage you to speak to your GP about testing from the age of 45. 'We don't think it's right that the responsibility is all on men's shoulders, so we're calling on the Health Secretary to overhaul outdated NHS guidelines so that GPs are empowered to actually start conversations with these men at highest risk.' A Government spokesperson said: 'This Government has been clear we would like to see screening in place but the decision must be evidence-led, which is why the UK National Screening Committee is looking at this as a priority – including reviewing the evidence for screening men with a family history of prostate cancer. 'While the review is taking place we are getting on with improving cancer treatment and prevention, as well as funding tens of millions of pounds of research.'
Daily Mail
3 hours ago
- Daily Mail
Top doctor reveals life-saving trio of daily foods that could ward off bowel cancer
A top doctor has detailed the cheap store cupboard essentials that can dramatically boost fibre intake—a key way to beat bowel cancer, according to experts. In an Instagram video, viewed 1.1 million times, Dr Karan Rajan, a surgeon working in NHS hospitals, dubbed his simple method 'fibermaxxing'. He said: 'If you want easy ways to fibermaxx with stuff you already have in your kitchen, I am going to show you just how simple it is.' Research shows that fibre—the indigestible parts of plants that aid digestion—plays a key role in preventing bowel cancer. Bowel Cancer UK estimates that a lack of the nutrient is behind 28 per cent of all cases in the UK—yet just nine per cent of adults eat the recommended 30g a day. The doctor suggests eating a combination of ingredients that are each five grams worth of fibre. The list he provides includes: 50g of pistachios or almonds, 80g of raspberries, 100g of frozen peas, 100g of hummus, 50g of dark chocolate and 75 grams of lentils. He also recommends fruits like an apple, avocado or a pear a day to boost fibre intake, adding: 'Combining any three for a fibre rich meal would be 15g of fibre.' View this post on Instagram A post shared by Dr Karan Rajan (MRCS MBBS BSc) (@drkaranrajan) He continues: 'When you stack fibre like this you are [also] getting it from three different sources all of which provide different phytonutrients, polyphenols and prebiotic fibres. 'These all have different impacts on your gut microbiome and their own special skill set.' Fibre is a type of carbohydrate in plants, but unlike sugar and starch it isn't absorbed by the body. Instead, it keeps the gut healthy and functioning properly. The nutrient is found in wholegrain cereals, beans, pulses, nuts, seeds, and fruit and vegetables. Research published earlier this year by experts at the University of California San Diego suggested that E-coli infections—a foodborne infection that damages the gut— is behind the rise in bowel cancer cases. Experts have previously told the Mail on Sunday that fibre could help protect against the infection blamed for the rise in cases. Dr Alasdair Scott, a gut specialist and science director at Selph—a health-testing firm —says high fibre intake is one of the few ways to counteract harmful in the gut. 'There's not much people can do if the bacteria does contribute to early onset colon cancer,' he says. 'But we do know that a high-fibre diet can protect against the type of mutation that causes tumours to develop.' Bowel cancer is on the rise in younger adults, even as rates fall among older generations. People born in 1990 are three times more likely to develop bowel cancer than those born in the 1950s, according to global research. In the UK, the disease kills nearly 17,000 people a year. While the vast majority of cases still occur in over-50s, around five per cent now affect adults aged 25 to 49—and that figure is steadily climbing. The main symptoms include changes in toilet habits, such as softer stools, diarrhoea or constipation. Going more or less often than usual, blood in the stool, or a feeling that you still need to go even after just going, can also be warning signs. Cancer Research UK estimates that more than half—54 per cent—of bowel cancer cases are preventable. Known risk factors include a diet low in fibre, eating too much red or processed meat, and obesity.
Scottish Sun
3 hours ago
- Scottish Sun
New ‘Ozempic pill' is better than ‘skinny jabs' and helps you lose weight even faster, study suggests
The new weight loss pill has seen promising results and offers hope to millions WEIGH TO GO New 'Ozempic pill' is better than 'skinny jabs' and helps you lose weight even faster, study suggests Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A NEW 'Ozempic pill' leads to faster weight loss than the popular 'skinny jabs', studies have suggested. The new weight loss medication, which can also be offered by injection, can help patients lose a significant amount of weight. Sign up for Scottish Sun newsletter Sign up 1 The new weight loss pill has seen promising results in early trials Credit: Getty An early study found that patients who received amycretin as a weekly jab lost 24% of their body weight after 36 weeks of treatment. But initial trials assessing a tablet form of the jab saw promising results with patients losing an average 13% of bodyweight in just three months. This suggests the drug leads to greater weight loss than Wegovy, the 'sister jab' of Ozempic. Such treatments have been called transformative by NHS leaders. It's estimated that around 1.5 million Brits currently receive weight loss jabs through specialist weight loss services or private prescriptions. But weight pills offer a new hope to millions looking to lose weight as the injections put additional pressure on an overstretched NHS. However, further clinical trials are needed before the treatment can be made available in the UK. This could take several years and there's no guarantee that regulators will approve the use of the drug. Amycretin, made by Novo Nordisk, contains semaglutide, the same active ingredient as Ozempic and Wegovy and helps control blood sugar and appetite. It targets specific receptors in the body - the GLP-1 and amylin receptors - helping you feel full and stops overeating. An early trial published in The Lancet found that 125 adults taking weekly injections containing higher doses of the drug lost nearly a quarter of their body weight after 36 weeks. It also showed signs of improving blood sugar levels. However, there were some mild to moderate side effects including nausea and vomiting but these were resolved by the end of the treatment. Experts said that the medicine appeared "safe and tolerable" but further studies were needed to fully assess the drug. But a second trial, also published in The Lancet, assessed the drug in tablet form in 144 people. Those taking the highest dose of 100mg lost 13% of their body weight over four months. Weight Loss Jabs - Pros vs Cons The authors wrote: "Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people who were overweight or obese. "Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen." As with the first trial, there were also some mild to moderate side effects including loss of appetite and similar gastrointestinal issues. It comes as a separate study examined the effects of the weight-loss jab, Wegovy, at higher doses. The researchers found that giving patients 7.2mg of Wegovy once a week led to an average weight loss of 21%, with a third of participants losing 25% of their body weight over 72 weeks. The studies were also presented to the American Diabetes Association's Scientific Sessions in Chicago.
